Cardiovascular Eligibility Criteria and Adverse Event Reporting in Combined Immune Checkpoint and VEGF Inhibitor Trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cardiovascular Eligibility Criteria and Adverse Event Reporting in Combined Immune Checkpoint and VEGF Inhibitor Trials

Published:2024-04 Issue:2 Volume:6 Page:267-279
ISSN:2666-0873
Container-title:JACC: CardioOncology
language:en
Short-container-title:JACC: CardioOncology

Author:

Rankin Stephen,Elyan Benjamin,Jones Robert,Venugopal Balaji,Mark Patrick B.,Lees Jennifer S.,Petrie Mark C.,Lang Ninian N.

Funder

Roche Diagnostics Corp

British Heart Foundation

Publisher

Elsevier BV

Reference32 articles.

1. Prevalence of cardiovascular disease in patients with potentially curable malignancies;Battisti;J Am Coll Cardiol CardioOnc,2022

2. Incident cardiovascular disease among adults with cancer;Paterson;J Am Coll Cardiol CardioOnc,2022

3. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non–small cell lung cancer treated with nivolumab;Topalian;JAMA Oncol,2019

4. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma;Heo;J Clin Pharm Ther,2021

5. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque;Drobni;Circulation,2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pumping Up the Standards;JACC: CardioOncology;2024-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP